CAS: 2315-02-8; Oxymetazoline Hydrochloride

该化合物是一种主要用作时热消融剂的共振代谢剂,它属于非硝化氮化合物类别,通常在鼻涕喷雾和眼滴中发现.该物质刺激甲型亚甲状腺受体,导致鼻腔肌肉受体血管收缩,从而减少肿胀和拥堵.奥氧甲基甲酸盐的特征是其行动时间相对较长,能够有效缓解冷冻,过敏或鼻炎造成的鼻塞.它通常在一种种族混合物中施用,并因其快速开始作用而闻名.虽然一般可以在短期内使用,但长期应用会导致反弹性拥堵,一种被称为鼻炎内膜内膜的症状.该化合物在水中溶解,其pH值范围与肌肉组织相容,这提高了其在药物配方的可用性.与任何药物一样,它必须遵循有关减少副作用和副作用的准则.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    📜6-(Tert-Butyl)-3-(2,2-Dibromovinyl)-2,4-Dimethylphenol,乙二胺 以95 %的收率获得盐酸羟甲唑啉
    参考文献:Cn115784996
    标题:Cn115784996

    海关参考信息

    专利信息


    专利号:US-2003138490-A1
    优先权日:2001-09-08
    标 题 :Synthesis and uses of polymer gel nanoparticle networks
    发明人:HU ZHIBING; LU XIHUA; GAO JUN; PONDER BILL C; JOHN JOHN ST; MORO DANIEL G
    摘要:Disclosed is a new class of nanostructured polymeric materials comprising polymer gel nanoparticles that are covalently bonded through functional groups on the surfaces of neighboring particles. These nanoparticles may be prepared as suspensions in an aqueous or, non-aqueous environment. These gels have two unique and different structural networks; the primary network comprises crosslinked polymer chains in each individual particle, while the secondary network is a system of crosslinked nanoparticles. Particular polymer gel nanoparticle network compositions disclosed herein may function as carriers for controlled delivery of pharmaceuticals or other chemical agents, gel sensors and other commercial applications.

    专利号:US-2006247308-A1
    优先权日:1999-05-14
    标 题:Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
    发明人:KATZ STANLEY E; MARTIN ALAIN
    权利人:KATZ STANLEY E; MARTIN ALAIN
    摘要:A method for treating the disease state in mammals caused by mammalian nasal and sinus cells involved in the inflammatory response is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

    专利号:EP-1183022-B1
    优先权日:1999-05-14
    标题 :Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response
    发明人:KATZ STANLEY E; MARTIN ALAIN
    权利人:CELLULAR SCIENCES INC
    摘要:A method for treating the disease state in mammals caused by a mammalian nasal and sinus cells involved in the inflammatory responser is disclosed. Mammalian nasal and sinus cells participating in the inflammatory response are contacted with an inflammatory response mediator which reduces the undesired inflammatory response and is an antioxidant. The inflammatory response mediator may further provide a cellular energy source and be a building block in the cellular synthesis of other cellular components. Compositions for reducing and treating undesired inflammatory response are also disclosed.

    专利号:US-7531164-B2
    优先权日:2005-10-21
    标 题 :Preventing bacterial or viral infectivity and composition containing infection preventing additive
    发明人:DAAKA YEHIA; STAMLER JONATHAN S
    权利人:UNIV DUKE
    摘要:A nitric oxide synthesis inhibitor or nitric oxide scavenger is administered to prevent development of infection, to prevent development of a cancer where overstimulation of a receptor contributes to the cancer development, and to prevent loss of beta agonist responsivity and as a treatment in combination with a receptor blocker. Compositions include nitric oxide synthesis inhibitor or nitric oxide scavenger containing spermicidal compositions, nasal steroid compositions, urinary tract infection prophylaxis compositions, compositions for prophylaxis of EGFR associated cancer and human blood component(s) composition for transfusion.

    专利号:US-2018230127-A1
    优先权日:2015-08-13
    标题 :Bicyclic-Fused Heteroaryl Or Aryl Compounds
    发明人:ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; GAVRIN LORI KRIM; GOLDBERG JOEL ADAM; LEE ARTHUR; LOWE MICHAEL DENNIS; PATNY AKSHAY; PIERCE BETSY SUSAN; SAIAH EDDINE; TRZUPEK JOHN DAVID
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds of Formula (Ia) are disclosed which are inhibitors of Interleukin-1 receptor associated kinase (IRAK4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.

    专利号:US-9879022-B2
    优先权日:2014-04-04
    标题:Bicyclic-fused heteroaryl or aryl compounds
    发明人:TRZUPEK JOHN DAVID; LEE KATHERINE LIN; BUNNAGE MARK EDWARD; HAN SEUNGIL; HEPWORTH DAVID; LOVERING FRANK ELDRIDGE; MATHIAS JOHN PAUL; PAPAIOANNOU NIKOLAOS; PIERCE BETSY SUSAN; STROHBACH JOSEPH WALTER; WRIGHT STEPHEN WAYNE; ZAPF CHRISTOPH WOLFGANG; GAVRIN LORI KRIM; LEE ARTHUR; ANDERSON DAVID RANDOLPH; CURRAN KEVIN JOSEPH; DEHNHARDT CHRISTOPH MARTIN; SAIAH EDDINE; GOLDBERG JOEL ADAM; WANG XIAOLUN; HUANG HORNG-CHIH; VARGAS RICHARD; LOWE MICHAEL DENNIS; PATNY AKSHAY
    权利人:PFIZER
    摘要:Compounds, tautomers and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula Ia, n nas defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kirtsreesakul V, Khanuengkitkong T, Ruttanaphol S. Does oxymetazoline increase the efficacy of nasal steroids in treating nasal polyposis? Am J Rhinol Allergy. 2016 May;30(3):195-200. doi: 10.2500/ajra.2016.30.4294. doi: 10.12932/AP0649.34.1.2016. doi: 10.1016/j.adaj.2015.12.008. Epub 2016 Jan 25. doi: 10.1177/0003489415617776. Epub 2015 Nov 26.
    7: Nordt SP, Vivero LE, Cantrell FL. Not Just a Drop in the Bucket-Inversion of Oxymetazoline Nasal Decongestant Container Increases Potential for Severe Pediatric Poisoning. J Pediatr. 2016 Jan;168:240-1. doi: 10.1016/j.jpeds.2015.09.067. Epub 2015 Oct 30. doi: 10.2500/aap.2015.36.3879. Epub 2015 Jun 29. doi: 10.1115/1.4030825. Epub 2015 Jun 23. doi: 10.1097/DSS.0000000000000362.

    合成参考文献


    参考文献:10.1007/s10337-025-04390-y
    摘要:Kulkarni SV, Lokhande S, Musmade BD, Bhope SG, Nagar M, Panchgalle SP, More VS. Quantification of Seven Known and Several Unknown Impurities from Fluticasone Furoate and Oxymetazoline Hydrochloride Nasal Spray Product Using RP-HPLC UV Methodology. Chromatographia. 2025 Feb 10;88(3):243–55. doi: 10.1007/s10337-025-04390-y.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知